Dr. Michael Kelly
Dr. Michael Kelly joined CureDuchenne in December 2011 as chief scientific officer. Kelly, a senior pharmaceutical executive, brings more than 25 years experience in drug discovery and development to the organization. He is responsible for advancing drug development programs and identifying new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy.
Before joining CureDuchenne, Kelly served as president and U.S. site head of Renovis, Inc. and has held senior positions at Amgen, Inc., Wyeth (Pfizer) and Wellcome (GlaxoSmithKline).
Kelly holds a Ph.D. from the University of Southampton (U.K.), held research positions at the University of Michigan and University of Nottingham, is an inventor on more than 100 patents and is widely published in peer reviewed journals.